Genmab — November 2019
-
-
Poster Conclusion: Here we show for the first time that, although follow-up is still short, the combination of daratumumab and nivolumab may be a new therapeutic regimen with an acceptable safety profile in RRMM - 1879 Efficacy and Safety of Nivolumab Combined with Daratumumab - https://ash.confex.com/ash/2019/webprogram/Paper124339.html
-
Måske det er gammelt nyt her (?), men ellers en artikel fra oktober: "Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer". https://insight.jci.org/articles/view/128199
-
Hej ...Kan godt bruge et par ekstra spørgsmål.
-
Især vedr. regnskab.
-
Det er kun Jan denne gang.
-
Prøv at skrive ind i Q&A chatten.
-
Jeg kan se på kursen, at Q&A effekten har indfundet sig .
-
Spørg endelig KKjoel.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind